Abstract
BAG-1 is a recently identified Bcl-2-interacting anti-apoptotic protein. The aim of our study was to investigate the immunohistochemical staining pattern of BAG-1 protein in patients with colorectal cancer and examine associations of BAG-1 expression with various clinicopathological factors and patient survival. Tumour samples were collected from 86 patients diagnosed with colorectal cancer. There was significant variation in the immunohistochemical staining patterns for BAG-1, including absent staining and staining of either the cytoplasm, nucleus or both. Twenty-one colorectal carcinomas (24.4%) exhibited a nuclear staining pattern whilst 56 (65.1%) exhibited cytoplasmic staining. The percentage of cases exhibiting nuclear BAG-1 positivity was significantly higher in distant metastasis-positive cases (55.6%) than in distant metastasis-negative cases (20.8%; P=0.036). Overall survival was significantly shorter for patients with tumours exhibiting BAG-1 positive nuclei than those with absent nuclear BAG-1-staining (P=0.011). In addition, the multivariate cox proportional hazard models indicated that nuclear BAG-1 expression was the only independent prognostic variable for mortality (P=0.013). These studies demonstrate that nuclear BAG-1 expression is a useful predictive factor for distant metastasis and a poor prognosis in patients with colorectal cancer.
Similar content being viewed by others
Main
Recent studies have suggested that apoptosis is controlled by a variety of genes, with dysregulation of these genes playing an important role in the pathogenesis of many human diseases including cancer (Oltvai et al, 1993; Soini et al, 1996; Koshida et al, 1997). BAG-1 protein was originally identified as a novel regulator of apoptosis by virtue of its ability to bind Bcl-2, a potent inhibitor of cell death, and it not only independently inhibits apoptosis but also enhances the anti-apoptotic activity of Bcl-2 (Takayama et al, 1995). Moreover, variations in BAG-1 levels parallel alterations in cellular proliferation and viability (Clevenger et al, 1997). Despite extensive studies of the function of BAG-1, the exact role of BAG-1 in the carcinogenesis and progression of human colorectal cancers remains unclear. In addition, discrepant results regarding BAG-1 immunostaining and patient survival in early breast cancer have been in dispute (Tang et al, 1999; Turner et al, 2001). In the present study, we used a polyclonal antibody that allowed specific detection of human BAG-1 protein and examined the immunohistochemical staining patterns of BAG-1 protein in patients with colorectal cancer. We also determined associations between the BAG-1 expression pattern and various clinicopathological factors and patient survival.
Materials and methods
Patients and tumour samples
A total of 86 adenocarcinomas of the colon and rectum were studied. Tumours were obtained surgically between 1991 and 1995 at the Department of Surgery II, Oita Medical University. All specimens were fixed in 10% buffered formalin and embedded in paraffin.
Immunohistochemical staining
Deparaffinized and rehydrated specimens were heated in 10 mM citrate buffer, pH 6.0, for 10 min in an autoclave at 121°C. After treatment with 10% normal goat serum for 10 min to block nonspecific protein binding, polyclonal BAG-1 antibody (rabbit antimouse, clone C-16; Santa Cruz CA, USA; 250 X dilution) was applied. Tissue sections were incubated overnight at 4°C. After brief rinsing, the Catalyzed Signal Amplification system (DAKO Corp.) was used according to the manufacturer's instructions to visualise specific BAG-1 staining. After brief washing, sections were incubated with diaminobenzidine and H2O2 for 5 min. Sections were then lightly counterstained with haematoxylin, dehydrated in graded alcohols, cleared in xylene and coverslipped.
The immunopositive cell area was used for evaluation of the immunohistochemical staining of BAG-1 antibody: negative 0–10%; positive >10%. Expression of BAG-1 was also evaluated in terms of immunostaining of the tumour cell nucleus and cytoplasm. A clinicopathological study was performed by reference to mean tumour diameter, depth of invasion, histological grade of adenocarcinoma and the presence of lymph node or distant metastasis.
Statistical analysis
Correlations between antigen expression and the various clinicopathological factors (mean tumour diameter, depth of invasion, histological grade of adenocarcinoma and the presence of lymph node or distant metastasis) were examined by the Student's t-test, chi-squared test, Fisher's exact probability or Mann–Whitney's U-test. Overall survival was calculated according to the Kaplan–Meier method, from the time of operation to either death or date of last follow-up, and the log-rank test was used to determine statistical differences between life tables. The multivariate cox proportional hazards model was used to determine whether any of the factors tested (tumour diameter, depth of invasion, histological grade of adenocarcinoma, lymph node metastasis and nuclear or cytoplasmic immunohistochemical expression for BAG-1) could be identified as independent prognostic factors for overall patient survival. A P value of less than 0.05 was considered statistically significant.
Results
Immunohistochemical staining of BAG-1
There was significant variation in the immunohistochemical staining patterns of BAG-1 with tumours exhibiting absent staining and staining of either the cytoplasm, nucleus or both. The distinction between cytoplasmic and nuclear BAG-1 staining is demonstrated in Figure 1A,B. Twenty-one colorectal carcinomas (24.4%) exhibited a nuclear staining pattern whilst 56 (65.1%) exhibited a cytoplasmic staining pattern.
Correlations between the expression of BAG-1 and the various clinicopathological factors
Table 1 shows the correlations between the expression of BAG-1 and various clinicopathological factors. The percentage of tumours exhibiting nuclear BAG-1 positivity was significantly higher in cases positive for distant metastases (55.6%) compared to cases without distant metastases (20.8%; P=0.036; Fisher's exact probability). No other significant correlation was evident between nuclear or cytoplasmic BAG-1 expression and the various clinicopathological factors analysed.
Survival analysis
Overall survival, as determined by the Kaplan–Meier analysis, was significantly shorter for patients with tumours exhibiting nuclear BAG-1 positivity compared to those that were negative for nuclear BAG-1 staining (Figure 2A; log-rank test, P=0.011). Survival at 5 years was 51.3% in patients with tumours exhibiting nuclear BAG-1 positivity compared to 83.9% in those patients with tumours that were negative for nuclear BAG-1 staining. There was no significant difference in survival between patients with cytoplasmic BAG-1-positive tumours and those with cytoplasmic BAG-1-negative tumours (Figure 2B; log-rank test, P=0.955). Using the variables of tumour diameter, depth of invasion, histological grade of adenocarcinoma, lymph node metastasis, nuclear BAG-1 expression and cytoplasmic BAG-1 expression, the multivariate cox proportional hazard model indicated that nuclear BAG-1 expression was the only independent prognostic variable for mortality (Table 2: hazard ratio=3.572, P=0.013). The other clinicopathological factors were not significantly associated with patient survival.
Discussion
There have been few reports regarding the immunohistochemical staining pattern of BAG-1 in colorectal cancer. Immunohistochemical expression of BAG-1 detectable by antibody (C-16) staining is weak in colorectal mucosa (Takayama et al, 1998). Use of the standard avidin–biotin–peroxidase complex (ABC) technique that we usually employ (Kikuchi et al, 2000) indicates that approximately 5% of colorectal cancer cells exhibit nuclear or cytoplasmic positivity (data not shown). Hence, we used the Catalyzed Signal Amplification system (DAKO Corp.), which is an extremely sensitive immunocytochemical visualisation system to facilitate the accurate determination of the expression of BAG-1 in colorectal cancers. Indeed, this is the first large-scale retrospective study to assess the prognostic significance of BAG-1 expression in patients with colorectal cancer. We noted that tumour cells exhibited two patterns of immunohistochemical staining viz cytoplasmic or nuclear. Comparable cytoplasmic or nuclear staining patterns have been reported in other cancers (Brimmell et al, 1999; Tang et al, 1999; Yamauchi et al, 2001). The reason is as follows: the bag-1 gene of humans and mice can produce two major proteins as a result of alternative translation initiation sites in a common mRNA. The shorter isoform (BAG-1) is predominantly a cytoplasmic protein, while the longer isoform (BAG-1L) is mostly translocated to the nucleus through its nuclear localisation signal (Packham et al, 1997; Takayama et al, 1998). The BAG-1 antibody (C-16) used in this study should recognise all isoforms (Crocoll et al, 2000). In addition, the intracellular localisation of BAG-1 may be modulated by cellular conditions or the differentiation status of these epithelial cells (Yamauchi et al, 2001). As a result, the BAG-1 protein may be immunolocalised to the cytoplasm or nucleus in colorectal cancer cells.
There are several reports to indicate that the expression of BAG-1 correlates with the malignant potential of other carcinomas (Tang et al, 1999; Shindoh et al, 2000). We then studied the relationship between BAG-1 expression and clinicopathological factors and prognosis. The nuclear expression of BAG-1 correlated with the presence of distant metastases. In addition, the prognosis of patients with nuclear BAG-1-positive tumours was significantly worse than that of those with nuclear BAG-1-negative tumours. In contrast, the cytoplasmic expression of BAG-1 was not related to the clinicopathological factors examined or patient prognosis. Therefore, the nuclear expression of BAG-1 was impressively correlated with the malignant potential in colorectal cancer. BAG-1 has been reported to facilitate epithelial cell survival following detachment from the underlying extracellular matrix (Ruoslahti, 1996; Weaver et al, 1996) and to promote cell migration in human gastric cancer cells (Naishiro et al, 1999). These functions could contribute to the development of distant metastases in malignant tumours since the overexpression of BAG-1 in melanoma cells increases the metastatic potential of these tumour cells (Takaoka et al, 1997). In our study, the percentage of cases exhibiting nuclear BAG-1 positivity was significantly higher in distant metastasis-positive cases than in distant metastasis-negative cases. Previous studies have reported that the gain-of-function p53 mutants derive from human tumours upregulated the transcription of BAG-1 RNA and the expression of a reporter gene from the BAG-1 promoter (Yang et al, 1999). These data are very interesting, since the function of BAG-1 may be associated with carcinogenesis or malignant potential acting through mutant-p53 functions. In summary, we can conclude that nuclear BAG-1 expression is an indicator of malignant potential and is a poor prognostic marker in colorectal carcinoma.
Finally, we discuss the significance of the nuclear BAG-1 expression. The shorter BAG-1 isoform is predominantly a cytoplasmic protein, while the longer isoform (BAG-1L) is mostly translocated to the nucleus (Packham et al, 1997; Takayama et al, 1998). Moreover, BAG-1L protein is rarely expressed in normal tissues but is commonly expressed by tumour cell lines, and a change in BAG-1 mRNA translation frequently accompanies malignant transformation (Takayama et al, 1998). In short, the nuclear BAG-1 expression almost certainly indicates BAG-1L, and is likely to be relevant to the malignant potential. Interestingly, several studies have reported that nuclear BAG-1 expression correlated with reduced survival in patients with invasive breast cancer (Tang et al, 1999) and laryngeal cancer after radiation therapy (Yamauchi et al, 2001). Thus, it is reasonable to suppose that nuclear BAG-1 expression is closely related to the malignant potential. However, two papers reported that cytoplasmic BAG-1 expression represented a potential marker of improved survival in early-stage breast cancer patients (Turner et al, 2001) and nonsmall cell lung cancer patients (Rorke et al, 2001) whilst nuclear BAG-1 expression was not related to the malignant potential. It is likely that the discrepancy between results may be attributed to different antibody or organ specificity. We believe that it is not clear whether the discrepant results are in conflict, since the differences of BAG-1 localisation in cancer cells indicate different expression of BAG-1 isoforms, which may well have different biological functions. Our data strongly indicate that further studies are necessary in order to clarify the relationship between BAG-1 isoforms and BAG-1 functions.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Brimmell M, Burns JS, Munson P, McDonald L, O'Hare MJ, Lakhani SR, Packham G (1999) High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers. Br J Cancer 81: 1042–1051
Clevenger CV, Thickman K, Ngo W, Chang WP, Takayama S, Reed JC (1997) Role of BAG-1 in the survival and proliferation of the cytokine-dependent lymphocyte lines, Ba/F3 and Nb2. Mol Endocrinol 11: 608–618
Crocoll A, Blum M, Cato AC (2000) Isoform-specific expression of BAG-1 in mouse development. Mech Dev 91: 355–359
Kikuchi R, Noguchi T, Takeno S, Kubo N, Uchida Y (2000) Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer 83: 215–218
Koshida Y, Saegusa M, Okayasu I (1997) Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 75: 367–373
Naishiro Y, Adachi M, Okuda H, Yawata A, Mitaka T, Takayama S, Reed JC, Hinoda Y, Imai K (1999) BAG-1 accelerates cell motility of human gastric cancer cells. Oncogene 18: 3244–3251
Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609–619
Packham G, Brimmell M, Cleveland JL (1997) Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation. Biochem J 328: 807–813
Rorke S, Murphy S, Khalifa M, Chernenko G, Tang SC (2001) Prognostic significance of BAG-1 expression in nonsmall cell lung cancer. Int J Cancer 95: 317–322
Ruoslahti E (1996) RGD and other recognition sequences for integrins. Annu Rev Cell Dev Bi 12: 697–715
Shindoh M, Adachi M, Higashino F, Yasuda M, Hida K, Nishioka T, Ono M, Takayama S, Reed JC, Imai K, Totsuka Y, Kohgo T (2000) BAG-1 expression correlates highly with the malignant potential in early lesions (T1 and T2) of oral squamous cell carcinoma. Oral Oncol 36: 444–449
Soini Y, Virkajarvi N, Lehto VP, Paakko P (1996) Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer 73: 1025–1030
Takaoka A, Adachi M, Okuda H, Sato S, Yawata A, Hinoda Y, Takayama S, Reed JC, Imai K (1997) Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 14: 2971–2977
Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC (1995) Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 80: 279–284
Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM, Kochel K, Knee D, Scudiero D, Tudor G, Miller GJ, Miyashita T, Yamada M, Reed JC (1998) Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumour cell lines. Cancer Res 58: 3116–3131
Tang SC, Shaheta N, Chernenko G, Khalifa M, Wang X (1999) Expression of BAG-1 in invasive breast carcinomas. J Clin Oncol 17: 1710–1719
Turner BC, Krajewski S, Krajewska M, Takayama S, Gumbs AA, Carter D, Rebbeck TR, Haffty BG, Reed JC (2001) BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol 19: 992–1000
Weaver VM, Fischer AH, Peterson OW, Bissell MJ (1996) The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumourigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. Biochem Cell Biol 74: 833–851
Yamauchi H, Adachi M, Sakata K, Hareyama M, Satoh M, Himi T, Takayama S, Reed JC, Imai K (2001) Nuclear BAG-1 localization and the risk of recurrence after radiation therapy in laryngeal carcinomas. Cancer Lett 165: 103–110
Yang X, Pater A, Tang SC (1999) Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumour-derived p53 mutants. Oncogene 18: 4546–4553
Acknowledgements
The authors thank Miss Naomi Kawano, Miss Yoko Iwata, and Miss Kaori Soe for technical assistance in immunohistochemical staining.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kikuchi, R., Noguchi, T., Takeno, S. et al. Nuclear BAG-1 expression reflects malignant potential in colorectal carcinomas. Br J Cancer 87, 1136–1139 (2002). https://doi.org/10.1038/sj.bjc.6600579
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600579
- Springer Nature Limited
Keywords
This article is cited by
-
BAG-1 suppresses expression of the key regulatory cytokine transforming growth factor β (TGF-β1) in colorectal tumour cells
Oncogene (2013)
-
The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells
Cell Death & Disease (2012)
-
BAG-1 interacts with the p50–p50 homodimeric NF-κB complex: implications for colorectal carcinogenesis
Oncogene (2012)
-
The relationship between Bag-1 and gastric cancer clinicopathologic characteristic
The Chinese-German Journal of Clinical Oncology (2011)
-
Correlation between the expression of the BAG-1 gene and clinicopathologic factors in colorectal cancer
Journal of Cancer Research and Clinical Oncology (2011)